Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPHZQE)

Drug Name
Chlorpropamide Drug Info
Synonyms
Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [1]
Therapeutic Class
Hypoglycemic Agents
Cross-matching ID
PubChem CID
2727
ChEBI ID
CHEBI:3650
CAS Number
CAS 94-20-2
TTD Drug ID
DMPHZQE
VARIDT Drug ID
DR00478
INTEDE Drug ID
DR0311
ACDINA Drug ID
D00125

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Inward rectifier potassium channel Kir1.2 (KCNJ10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [8]
Glisoxepide DMJPR2B Non-insulin dependent diabetes 5A11 Approved [9]
Gliquidone DMB0EUX Diabetic complication 5A2Y Approved [10]
Tolazamide DMIHRNA Diabetic complication 5A2Y Approved [11]
Mitiglinide DMP8HEL Diabetic complication 5A2Y Approved [12]
Glycodiazine DM1WL9O Diabetic complication 5A2Y Approved [13]
Sulfonylthioureas DMBG0H1 Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [17]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [18]
Verapamil DMA7PEW Angina pectoris BA40 Approved [20]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [21]
Estrone DM5T6US Acne vulgaris ED80 Approved [22]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [24]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [25]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [26]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [18]
Verapamil DMA7PEW Angina pectoris BA40 Approved [27]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [28]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [23]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [29]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein c-Fos (FOS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [31]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [32]
Verapamil DMA7PEW Angina pectoris BA40 Approved [6]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [33]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [6]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [34]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [35]
Methotrexate DM2TEOL Anterior urethra cancer Approved [36]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Vasopressin-neurophysin 2-copeptin (AVP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [39]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [40]
Oxprenolol DM51OQW Anxiety Approved [41]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [43]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [44]
Luvox DMJKROX Anxiety disorder 6B00-6B0Z Approved [45]
Sodium chloride DMM3950 Skin burns ME65.0 Approved [46]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [40]
Indomethacin DMSC4A7 Bursitis Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Insulin (INS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [48]
Methotrexate DM2TEOL Anterior urethra cancer Approved [49]
Epinephrine DM3KJBC Acute asthma CA23 Approved [50]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [51]
Fructose DM43AN2 Vomiting MD90 Approved [52]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [53]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [5]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [54]
Propranolol DM79NTF Angina pectoris BA40 Approved [55]
Testosterone DM7HUNW Hot flushes GA30 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Angiotensin-converting enzyme 2 (ACE2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Captopril DM458UM Chronic heart failure BD1Z Approved [57]
Diazepam DM08E9O Alcohol withdrawal Approved [4]
Dantrolene DM1D8XY Hyperthermia MG26 Approved [4]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [4]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [4]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [4]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [4]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [4]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [4]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inward rectifier potassium channel Kir1.2 (KCNJ10) TTG140O KCJ10_HUMAN Blocker [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [3]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [4]
Insulin (INS) OTZ85PDU INS_HUMAN Gene/Protein Processing [5]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Gene/Protein Processing [6]
Vasopressin-neurophysin 2-copeptin (AVP) OTAVZ76K NEU2_HUMAN Protein Interaction/Cellular Processes [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6801).
2 Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
3 Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
4 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
5 Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
6 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
7 Inappropriate secretion of antidiuretic hormone induced by chlorpropamide. Am J Med Sci. 1972 Mar;263(3):137-41. doi: 10.1097/00000441-197203000-00002.
8 Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
9 Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
10 Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
11 Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
12 Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
13 Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
14 Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
15 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
16 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
17 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
18 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
20 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
21 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
22 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
23 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
24 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
25 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
26 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
27 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
28 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
29 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
30 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
31 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
32 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
33 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
34 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
35 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
36 Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
37 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
38 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
39 [Increased secretion of vasopressin and edema formation in high dosage methotrexate therapy]. Z Gesamte Inn Med. 1988 Aug 1;43(15):411-4.
40 Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone. Brain. 1983 Jun;106 (Pt 2):503-11. doi: 10.1093/brain/106.2.503.
41 Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension. Acta Med Scand. 1984;215(2):165-72. doi: 10.1111/j.0954-6820.1984.tb04988.x.
42 Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry. 1987 Apr;22(4):453-62. doi: 10.1016/0006-3223(87)90167-3.
43 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
44 Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11(6):377-84. doi: 10.1080/080370502321095357.
45 [Three cases of severe hyponatremia under taking selective serotonin reuptake inhibitor (SSRI)]. Nihon Jinzo Gakkai Shi. 2000 Oct;42(8):644-8.
46 Osmoregulation of vasopressin and thirst: comparison of 20% mannitol with 5% saline as osmotic stimulants in healthy man. Clin Endocrinol (Oxf). 1994 Aug;41(2):207-12. doi: 10.1111/j.1365-2265.1994.tb02531.x.
47 Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. Pediatr Nephrol. 2005 Nov;20(11):1552-6. doi: 10.1007/s00467-005-2022-6. Epub 2005 Aug 17.
48 Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
49 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
50 A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
51 Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
52 Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
53 Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
54 Clonidine effect on insulin secretion and lipolysis in man. Acta Diabetol Lat. 1978 May-Aug;15(3-4):192-7. doi: 10.1007/BF02581064.
55 Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
56 Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
57 Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.